last updated 23-12-2009
Pharmaceutical package
Pharmaceutical package: a short-sighted vision that puts patients’ at risk
A thorough analysis of the "Pharmaceutical package" content (proposals on "patient-information", "pharmacovigilance" and "fake medicines") reveals that the EU Commission is upholding the competitiveness of Europe’s pharmaceutical industry thus overriding public interests.
March 2009
Legal proposals on “information” to patients by pharmaceutical companies: a threat to public health
The implementation of “Direct-to-consumer advertising” (DTCA) in Europe has been a priority for pharmaceutical companies since the last EU pharmaceutical legislation review in 2001. This is however a useless exercise for both Europeans and Member States, representing additional bureaucracy and increased cost and putting patients at risk, that is why the proposals need to be withdrawn.
March 2009